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DNA fragments containing (AT). inserts cloned adjacent o putative mithramycin binding sites have been examined by footprinting experiments 
using a variety of nucleases in the presence of the drug. The results demonstrate that mithramycin induces a DNA structural change which renders 
adjacent (AT), sequences sensitive to attack by DNase II. Significant changes are also revealed with DNase I and micrococcal nuclease. The results 
are consistent with a model in which mithramycin opens the DNA minor groove changing it to a structure which is locally more like A-DNA. 
Mithramycin; DNase I; Footprinting; DNA structure; (AT),, 
1. INTRODUCTION 2. MATERIALS AND METHODS 
Mithramycin is an antitumour antibiotic which acts 
by binding to DNA thereby inhibiting its function as a 
template for DNA-directed RNA polymerase [ 1,2]. 
This interaction requires magnesium [3] and the 
presence of guanine bases [4]. Previous footprinting 
studies using methidiumpropyl-EDTA [5], DNase I [6], 
and hydroxyl radicals [7] have confirmed this selectivity 
and suggested that the recognition site consists of the 
dinucleotide step GpG. 
Since nucleases produce DNA cleavage patterns 
which are dependent on local DNA structure they can 
be used to report conformational changes which ac- 
company drug binding. DNase I footprinting studies 
have revealed that many ligands cause increases in en- 
zyme activity in regions surrounding their binding sites 
[8,9]. Previous footprinting studies have either used 
natural DNAs of random sequence [5-91 or short 
oligonucleotides [lO,l l] as substrates. Enhancements in 
the former are difficult to interpret rigorously because 
of the large number of closely related binding sites, 
while the latter can be criticised on account of the short 
size of the DNA which may be subject to end effects. 
In this paper we investigate the effects of mithramycin 
on nuclease digestion patterns of DNA fragments con- 
taining regions of alternating A and T adjacent to 
isolated mithramycin binding sites. 
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2.1. Drugs and enzymes 
Mithramycin was a gift from Pfizer USA and was stored as a 2 mM 
stock solution in 10 mM Tris-HCI containing 10 mM NaCl. DNase 
I, DNase II and micrococcal nuclease were purchased from Sigma. 
2.2. DNA fragments 
Plasmids containing alternating AT inserts cloned within the SmaI 
site (CCWGGG) were prepared as follows. Poly(dA-dT) (Boehr- 
inger) was cut to short lengths by mild digestion with DNase I and 
the fragments were blunt-ended by filling with dATP and dTTP using 
reverse transcriptase. These were then ligated into SmaI cut pUC13 
and transformed into E. co/i TG2. Transformants were picked in the 
usual way as white colonies and their sequences were determined by 
Maxam-Gilbert reactions. The 3 fragments used in this work contain- 
ed (TAb, (AT)eA and (TA)ia in the SmaI site within the local se- 
quence TCGCCCYGGGGAT. Radiolabelled DNA fragments 
containing these inserts were prepared by digesting the plasmids with 
HindIII, labelhng with [~Y-~*P]~ATP and cutting again with EcoRI. 
These were then purified from 8% polyacrylamide gels. 
2.3. Footprinting and gel electrophoresis 
Footprinting with DNase I, DNase II and micrococcal nuclease 
(MNase) was performed as previously described [8,9,12]. In each case 
1 mM MgClz was included in the reaction since this is required for 
mithramycin binding [4]. The products were resolved on 10% (w/v) 
polyacrylamide gels containing 8 M urea. Bands in DNase I digests 
were assigned by comparison with Maxam-Gilbert sequencing reac- 
tions. Since DNase II and MNase generate radiolabelled products 
which terminate in a 5 ’ -hydroxyl, in contrast o DNase I and Maxam- 
Gilbert reactions which end in a 5 ‘-phosphate he products of the two 
reactions have different gel mobilities. Products from MNase 
cleavage were easily assigned since this enzyme cuts only pA and pT 
bonds [12], these were then used as markers for DNase II digestion. 
3. RESULTS 
3.1. DNase I footprinting 
Fig. 1 presents DNase I digests of the (TA)re, (TA)6T 
and (TA)s containing DNA fragments in the presence 
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Fig, I. DW;rse f dissts of the (TA)sr (AT)& and (TA)lo containing DNA fragments itr the presence and absence of mithr;arnycin. Each fragment 
Iabelled at the 3’-end of the Hind111 site. The square brackets indicate the position of the inserts. The track labelled Cr is a Maxam-Gilbert 
dirnethy~s~~b~te piperidine marker specific for guanirre. Each pair of lanes corresponds to digestion by the enme for 1 and 5 min. Drug 
~~~~tra~o~s f&4) are show3 at the top of each pair of Ianes. 
and absew~ of various co~ce~t~~tio~s f mithramycin. 
In the absence of the antibiotic alI 3 fragments show 
cleavage at TpA but not ApT as expected [ 13,141. In 
the presence af mithramycin clear footprints can be 
seen at either end of the inserts correriponding to the se- 
quence GGG (CCC). More bonds are protected 
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Fig. 2. MNase digests of the (AT)& and (TA)lo containing DNA fragments in the presence and absence of mithramycin. The square brackets 
indicate the position of the inserts. Each pair of lanes corresponds to digestion by the enzyme for 1 and 5 min (reading right to left). The track 
labelled ‘A’ corresponds to a KzPdCL+-piperidine marker specific for adenine [22]. Drug concentrations (/rM) are shown at the top of each pair 
of lanes. 
towards the upper (5’) side of the insert, since DNase 
I footprints are staggered towards the 3 ‘-side of drug 
binding sites. In the presence of mithramycin, the 
preference for cutting ApT over TpA is retained and 
cleavage products from the latter are still barely visible. 
However, in each case there appears to be a significant 
increase in cutting throughout the insert. In the absence 
of quantitative footprinting studies it is not possible to 
assess whether this reflects a change in DNA conforma- 
tion or if it is simply due to alterations in the relative 
concentrations of free DNA and enzyme. 
3.2. Micrococcal nuciease &UVase) 
Fig. 2 presents the results of similar studies using 
MNase as the footprinting probe. This enzyme cuts ex- 
clusively at pA and pT bonds and is particularly active 
in regions of alternating AT [ 13,141. Cleavage is slight- 
ly better at TpA than ApT. In the presence of 
mithramy~in, the outermost MNase cleavage products 
are missing, presumably because of some steric occlu- 
sion by the adjacent drug molecule. In each case 
cleavage within the insert is increased and the cutting 
pattern is more even. This is especially noteworthy 
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Fig. 3. DNase II digests of the (TA)s, (AT)sA and (TA)lo containing DNA fragments in the presence and absence of mithramycin. Each pair 
of lanes corresponds to digestion by the enzyme for 1 and 5 min. The tracks labelled MN correspond to the products of MNase digestion and 
are useful for assigning the pA and pT bonds (see Fig. 2). The square brackets indicate the positions of the inserts. 
since MNase attack at other bonds outside the insert 
does not appear to have been altered. 
3.3. DNase II 
Fig. 3 presents the results of DNase II digestion of 
the same 3 DNA fragments in the presence and absence 
of mithramycin. This enzyme cuts the 05 ’ -P bond 
[ 15,161 especially in runs of purines, so that cleavage 
does not correlate across the two strands. It appears to 
recognise a peculiar DNA strand conformation which is 
possibly close to an A-like structure. As previously 
noted, this enzyme shows no cleavage in AT inserts 
[ 131. In the presence of mithramycin, cutting is greatly 
reduced around the GGG (protection at the upper CCC 
is not apparent since this is a very poor DNase II site). 
More interesting, however, are the novel cleavage pro- 
ducts apparent on the drug-treated lanes. It appears 
that mithramycin has somehow rendered portions of 
the AT inserts sensitive to DNase II attack. In each case 
the increased cleavage is greatest 8 bases from the 
3 ‘-end of the insert. 
4. DISCUSSION 
4.1. Structural changes induced by mithramycin 
Mithramycin binds in a non-intercalative fashion in 
the DNA minor groove, NMR studies have suggested 
that the drug binds as a dimer, coordinating a single 
magnesium ion, and that this large species causes a 
dramatic widening in the local width of the minor 
groove [17,18]. Does this binding model explain the 
observed changes in enzyme activity? The most 
dramatic changes are seen with DNase II. Although the 
precise structural requirements of this enzyme are not 
certain, it is known to cut the DNA strands asym- 
metrically with the best cleavage in runs of purines 
(especially G or G and A) [ 15,161. It has been proposed 
that the enzyme binds to one strand of the duplex and 
is sensitive to the orientation of 3 adjacent phosphate 
groups [ 151. It may be that this enzyme cuts DNA best 
when the strand conformation resembles something 
akin to A-DNA, with a very wide and shallow minor 
groove. Such a conformation has been proposed at the 
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mithramycin binding site [17,18]. It therefore seems 
that this altered conformation is transmitted into the 
adjacent runs of A and T. 
There is only one report of DNase II footprinting of 
mithramycin on a natural DNA fragment [19]. In this 
case, although drug-induced protections were observ- 
ed, no enhancement of enzyme activity was evident. 
However, this may be because this DNA sequence did 
not contain any regions of alternating AT; these may be 
peculiarly sensitive to drug-induced changes in 
structure. 
Although DNase I cleavage at ApT is increased, cut- 
ting of TpA appears to be unaffected, so that the alter- 
nating pattern of products is still apparent. The 
simplest interpretation of the DNase I data would be 
that mithramycin has further stabilised the alternating 
B-structure. Previous DNase I footprinting studies with 
tyrT DNA revealed enhancements in enzyme activity in 
the sequence ATAT (position 88) [6]. 
The changes in cleavage pattern observed with these 
DNA fragments are similar for all the different length 
inserts. The structural changes occur in an all-or-none 
fashion, consistent with the cooperative binding that 
has been detected for binding of several igands to po- 
ly(dA-dT). 
4.2. Comparison with other drugs 
Actinomycin [20] and echinomycin [21] also show 
changes in enzyme activity in regions of alternating AT 
surrounding their binding sites. How do these results 
with mithramycin compare with other data? Ac- 
tinomycin and echinomycin each alter the relative rates 
of DNase I cleavage at TpA and ApT so that the 
preference for cutting ApT is less pronounced. This 
contrasts with mithramycin which leaves the TpA step 
in an unreactive conformation. The changes in reactivi- 
ty of MNase are similar for all 3 drugs, causing an in- 
creased rate of cleavage in which both TpA and ApT 
bonds are cut at equal rates. Actinomycin induces 
DNase II cleavage in regions of alternating A and T 
which are sandwiched between two GpC sites; these ef- 
fects increase towards the centre of the insert in much 
the same way as mithramycin. 
Two important points can be drawn from these 
observations. Firstly the changes in enzyme activity are 
different for various ligands. Each drug induces 
characteristic hanges in DNA structure. Secondly the 
results emphasise the importance of using a wide range 
of enzymic probes for studying the effects of drugs on 
DNA structure. 
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